Cara Therapeutics Inc (CARA) Given Consensus Recommendation of “Buy” by Analysts

Cara Therapeutics Inc (NASDAQ:CARA) has received a consensus rating of “Buy” from the seventeen brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $25.96.

Several research analysts recently commented on CARA shares. Canaccord Genuity set a $25.00 target price on Cara Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 20th. Zacks Investment Research raised Cara Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, August 30th. Scotiabank upped their price objective on Cara Therapeutics from $31.00 to $31.50 and gave the stock an “outperform” rating in a research report on Tuesday, October 17th. BMO Capital Markets reaffirmed a “market perform” rating and set a $25.00 price objective on shares of Cara Therapeutics in a research report on Tuesday, November 7th. Finally, CIBC lowered their price objective on Cara Therapeutics from $26.00 to $24.00 in a research report on Tuesday, November 7th.

Cara Therapeutics (NASDAQ CARA) opened at $12.62 on Friday. Cara Therapeutics has a one year low of $8.70 and a one year high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.03). During the same period in the previous year, the business earned ($0.42) earnings per share. analysts anticipate that Cara Therapeutics will post -1.84 EPS for the current year.

In related news, CEO Derek T. Chalmers sold 16,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $12.66, for a total value of $202,560.00. Following the completion of the sale, the chief executive officer now directly owns 1,066,292 shares of the company’s stock, valued at approximately $13,499,256.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc boosted its position in shares of Cara Therapeutics by 10.4% in the 2nd quarter. Legal & General Group Plc now owns 7,167 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 678 shares during the period. Fred Alger Management Inc. acquired a new stake in shares of Cara Therapeutics in the 2nd quarter valued at about $123,000. Capital Fund Management S.A. acquired a new stake in shares of Cara Therapeutics in the 2nd quarter valued at about $171,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Cara Therapeutics in the 3rd quarter valued at about $180,000. Finally, Rathbone Brothers plc acquired a new stake in shares of Cara Therapeutics in the 2nd quarter valued at about $185,000. 58.80% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/15/cara-therapeutics-inc-cara-given-consensus-recommendation-of-buy-by-analysts.html.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply